Endonovo Therapeutics, Inc.
February 6, 2019
Division of Corporate Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Endonovo Therapeutics, Inc. |
| Registration Statement Form S-1 – Acceleration Request | |
| File No. 333-229146 |
Dear Sirs and/or Madam:
This letter serves as our request, in accordance with Rule 461, for acceleration of the effectiveness of the above-referenced Registration Statement (filed pursuant to Form S-1) to February 11, 2019 at 10:00 a.m., or as soon thereafter as practicable.
Very truly yours,
Endonovo Therapeutics, Inc.
| /s/ Alan Collier | |
| Alan Collier, CEO |
